Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors

All categories

DBCAT005753Pharmacologic classL01EN

A DrugBank category of 4 drugs. 4 of them are approved.

ATC classification: L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 — ANTINEOPLASTIC AGENTS
L01E — PROTEIN KINASE INHIBITORS
L01EN — Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors
Drugs: Erdafitinib
Futibatinib
Infigratinib
Pemigatinib

What you can answer from here — as of August 31, 2022

4DrugsEach linked to its full drug card

Listed above

11Drug targetsEvery drug–target pair in the class, with bond type

61Marketed productsAcross the regions we cover, with dosage forms and routes

1Route of administrationHow the drugs in this class are given

Which targets do Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account